Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/6/2026

1. HUBS
2. KVYO
3. ZG
4. DASH
5. APP
6. WDC
7. SNDK
8. XYZ
9. DOX
10. PAYC

Go back to Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
(NASDAQ: APVO) Delayed: 4.11 -0.08 (1.91%)
Previous Close $4.19    52 Week High $4.33 
Open $4.11    52 Week Low $1.80 
Day High $4.11    P/E N/A 
Day Low $4.10    EPS $0.00 
Volume 987